For about $75, the governments in South Africa and Kenya will soon be able to treat an HIV-infected person for 1 year with a pill taken once a day that contains a “best-in-class” combination of three antiretroviral (ARV) drugs.
Speaking openly about sex and HIV
The 2030 Agenda for Sustainable Development takes to scale what the AIDS response has been working towards for 30 years—a multisectoral, rights-based, people-centred approach that addresses the determinants of health and well-being. The individual stories in this series highlight the linkages between HIV and related Sustainable Development Goals (SDGs), each told from the personal perspective of people affected by HIV. The series paints a picture of how interconnected HIV is with the SDGs and how interdependent the SDGs are with each other. Most importantly, the stories show us the progress we have achieved with the AIDS response and how far we have left to go with the SDGs.
October 5, 2017
Researchers have been looking for ways to eliminate the "reservoirs" where the virus hides, and researchers from UCLA, Stanford University and the National Institutes of Health may have developed a solution.
Developing a vaccine to stop HIV is thought to be among the most daunting challenges in medicine for one big reason: The virus is extraordinarily genetically diverse, even more so than the flu. So it’s difficult to think about how a single shot might work against all the different HIV subtypes circulating around the world.
Cape Town- Aug 2017
Strengthening HIV Primary Prevention UNAIDS Discussion Papers:
A Civil Society Critique
The 90–90–90 targets are galvanizing global action and saving lives. Eastern and southern Africa leading the way in reducing new HIV infections by nearly 30% since 2010—Malawi, Mozambique, Uganda and Zimbabwe have reduced new HIV infection by nearly 40% or more since 2010. Concerted efforts still needed for children, adolescents, men and key populations, and in certain regions.